Ji Y, Xiao C, Fan T, Deng Z, Wang D, Cai W
Mol Cancer. 2025; 24(1):66.
PMID: 40038722
PMC: 11881328.
DOI: 10.1186/s12943-025-02255-4.
Barbeau L, Beelen N, Savelkouls K, Keulers T, Wieten L, Rouschop K
PLoS One. 2025; 20(2):e0316716.
PMID: 39928678
PMC: 11809862.
DOI: 10.1371/journal.pone.0316716.
Zhu H, Xiao C, Chen J, Guo B, Wang W, Tang Z
Cell Commun Signal. 2025; 23(1):42.
PMID: 39849460
PMC: 11755879.
DOI: 10.1186/s12964-024-02012-y.
Zhang T, Beytullahoglu O, Tulaiha R, Luvisotto A, Szczepanski A, Tsuboyama N
J Clin Invest. 2025; 135(2.
PMID: 39817454
PMC: 11735100.
DOI: 10.1172/JCI179703.
Jimenez-Rondan F, Ruggiero C, Riva A, Yu F, Stafford L, Cross T
Proc Natl Acad Sci U S A. 2025; 122(1):e2422321121.
PMID: 39793074
PMC: 11725848.
DOI: 10.1073/pnas.2422321121.
In situ licensing of mesenchymal stem cell immunomodulatory function via BMP-2 induced developmental process.
Zhu F, Ji L, Dai K, Deng S, Wang J, Liu C
Proc Natl Acad Sci U S A. 2024; 121(48):e2410579121.
PMID: 39565311
PMC: 11621467.
DOI: 10.1073/pnas.2410579121.
Dual blockade of IL-10 and PD-1 leads to control of SIV viral rebound following analytical treatment interruption.
Pereira Ribeiro S, Strongin Z, Soudeyns H, Ten-Caten F, Ghneim K, Pacheco Sanchez G
Nat Immunol. 2024; 25(10):1900-1912.
PMID: 39266691
PMC: 11436369.
DOI: 10.1038/s41590-024-01952-4.
A Ménage à trois: NLRC5, immunity, and metabolism.
Brunschwiler F, Nakka S, Guerra J, Guarda G
Front Immunol. 2024; 15:1426620.
PMID: 39035010
PMC: 11257985.
DOI: 10.3389/fimmu.2024.1426620.
Epigenetic regulation of major histocompatibility complexes in gastrointestinal malignancies and the potential for clinical interception.
Tovar Perez J, Zhang S, Hodgeman W, Kapoor S, Rajendran P, Kobayashi K
Clin Epigenetics. 2024; 16(1):83.
PMID: 38915093
PMC: 11197381.
DOI: 10.1186/s13148-024-01698-8.
Polycomb repressor complex 2 suppresses interferon-responsive MHC-II expression in melanoma cells and is associated with anti-PD-1 resistance.
James J, Taylor B, Axelrod M, Sun X, Guerin L, Gonzalez-Ericsson P
J Immunother Cancer. 2024; 11(11).
PMID: 38315170
PMC: 10660662.
DOI: 10.1136/jitc-2023-007736.
Mapping the splicing landscape of the human immune system.
Ner-Gaon H, Peleg R, Gazit R, Reiner-Benaim A, Shay T
Front Immunol. 2023; 14:1116392.
PMID: 37711610
PMC: 10499523.
DOI: 10.3389/fimmu.2023.1116392.
Strategies for overcoming bottlenecks in allogeneic CAR-T cell therapy.
Lv Z, Luo F, Chu Y
Front Immunol. 2023; 14:1199145.
PMID: 37554322
PMC: 10405079.
DOI: 10.3389/fimmu.2023.1199145.
The NLR member CIITA: Master controller of adaptive and intrinsic immunity and unexpected tool in cancer immunotherapy.
Forlani G, Shallak M, Gatta A, Shaik A, Accolla R
Biomed J. 2023; 46(5):100631.
PMID: 37467968
PMC: 10505679.
DOI: 10.1016/j.bj.2023.100631.
FBXO11 constitutes a major negative regulator of MHC class II through ubiquitin-dependent proteasomal degradation of CIITA.
Kasuga Y, Ouda R, Watanabe M, Sun X, Kimura M, Hatakeyama S
Proc Natl Acad Sci U S A. 2023; 120(24):e2218955120.
PMID: 37279268
PMC: 10268274.
DOI: 10.1073/pnas.2218955120.
Effects of post-transplant maintenance therapy with decitabine prophylaxis on the relapse for acute lymphoblastic leukemia.
Fan J, Lu R, Zhu J, Guo X, Wan D, Xie X
Bone Marrow Transplant. 2023; 58(6):687-695.
PMID: 36964223
DOI: 10.1038/s41409-023-01948-y.
Viral transduction of primary human lymphoma B cells reveals mechanisms of NOTCH-mediated immune escape.
Mangolini M, Maiques-Diaz A, Charalampopoulou S, Gerhard-Hartmann E, Bloehdorn J, Moore A
Nat Commun. 2022; 13(1):6220.
PMID: 36266281
PMC: 9585083.
DOI: 10.1038/s41467-022-33739-2.
Chromatin structure undergoes global and local reorganization during murine dendritic cell development and activation.
Kurotaki D, Kikuchi K, Cui K, Kawase W, Saeki K, Fukumoto J
Proc Natl Acad Sci U S A. 2022; 119(34):e2207009119.
PMID: 35969760
PMC: 9407307.
DOI: 10.1073/pnas.2207009119.
Transcriptional Plasticity Drives Leukemia Immune Escape.
Eagle K, Harada T, Kalfon J, Perez M, Heshmati Y, Ewers J
Blood Cancer Discov. 2022; 3(5):394-409.
PMID: 35709529
PMC: 9897290.
DOI: 10.1158/2643-3230.BCD-21-0207.
Clinical characteristics, treatment, and prognosis of 118 cases of myeloid sarcoma.
Zhao H, Dong Z, Wan D, Cao W, Xing H, Liu Z
Sci Rep. 2022; 12(1):6752.
PMID: 35474239
PMC: 9042854.
DOI: 10.1038/s41598-022-10831-7.
Chromatin-Remodeling Factor BRG1 Is a Negative Modulator of in IFNγ Stimulated and Infected THP-1 Cells.
Brar H, Roy G, Kanojia A, Madan E, Madhubala R, Muthuswami R
Front Cell Infect Microbiol. 2022; 12:860058.
PMID: 35433496
PMC: 9011159.
DOI: 10.3389/fcimb.2022.860058.